Background
Materials and methods
Patients
Patient (age in years, sex) | Antiretroviral Treatment | Duration (months) | CD4 nadir | CD4 baseline | |
---|---|---|---|---|---|
treatment
|
< 50 copies/mL
|
per uL (%)
|
per uL (%)
| ||
1 (65, M) | ZDV+3TC+EFV | 78 | 74 | 180 (13%) | 630 (38%) |
2 (53, M) | TDF+FTC+EFV | 124 | 82 | 200 (21%) | 550 (45%) |
3 (35, M) | ABC+ZDV+3TC+LPV/r | 75 | 38 | 20 (3%) | 200 (19%) |
4 (36, F) | ZDV+3TC+LPV/r | 54 | 48 | 50 (6%) | 330 (28%) |
5 (58, M) | ABC+DDI+EFV | 131 | 71 | 40 (4%) | 240 (19%) |
6 (36, M) | ZDV+3TC+EFV | 36 | 35 | 120 (7%) | 230 (18%) |
7 (43, M) | D4T+TDF+FTC+LPV/r | 35 | 21 | 40 (4%) | 530 (14%) |
8 (45, M) | TDF+FTC+NVP | 82 | 72 | 30 (2%) | 270 (19%) |
9 (43, M) | TDF+FTC+AZV/r | 78 | 67 | 90 (17%) | 920 (42%) |
Purification and quantification of resting memory CD4+ T-cells
Quantification of HIV-1 RNA in plasma
Viral RNA extraction from plasma and supernatants from activated memory T-cells
Single genome sequencing (SGS)
Phylogenetic analysis
Immunological assays
T-cell assays, flow cytometry, and mAbs
Cytokine analysis
Statistical analysis
Results
Subject | IUPM | Decrease | |
---|---|---|---|
Baseline
|
Week 8–12
|
of pool size
| |
2 | 28.3 | 5.6 | 80% |
3 | 1.6 | 0.5 | 68% |
7 | 1.6 | 0.5 | 68% |
8 | 1.6 | 0.5 | 68% |
9 | 3.2 | < 0.5 | >84% |
4 | 0.5 | 0.5 | |
6 | < 0.5 | 0.5 |